ET1402L1-ARTEMIS T cells

N/A

Report date: 2025/12/08 20:00:58

Base Information

Drug NameET1402L1-ARTEMIS T cells

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy

Mechanisms of ActionAlpha-fetoprotein inhibitors

TargetsAlpha-fetoprotein

Therapy Area/IndicationsLiver NeoplasmsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesAeon Therapeutics (Beijing) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAeon Therapeutics (Beijing) Co Ltd

Active IndicationsN/A

Inactive IndicationsLiver NeoplasmsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A